Skip to main content
Full access
Letter to the Editor
Published Online: 1 October 2002

Oxcarbazepine for Mood Disorders

To the editor: The Food and Drug Administration approved oxcarbazepine on Jan. 14, 2000, for the treatment of epilepsy. It has been reported to be effective in the treatment of mood disorders (1, 2). This report is about four Caucasian patients with bipolar II disorder with comorbid substance abuse who experienced significant improvement with oxcarbazepine.
Mr. A was a 52-year-old married man who was referred by a therapist in his employment assistance program for hostile behavior, which affected his relationships with family members and co-workers. He had been treated unsuccessfully with divalproate and psychotherapy. He began oxcarbazepine monotherapy, up to 1200 mg/day. He experienced better work productivity, an absence of physical violence toward his wife and co-workers, and fewer depressive days. He reported no side effects.
Ms. B was a 27-year-old single woman who was in treatment for childhood sexual abuse, self-mutilation, several suicide attempts, and episodic violent behavior. Since her adolescence, she had been in numerous inpatient and outpatient treatments, which had not produced significant improvement in her symptoms or function. Oxcarbazepine was initially added to her regimen of lorazepam, buproprion, fluvoxamine, trazodone, quetiapine, levothyroxine, and modafinil. Over the next year, she reduced her medications to oxcarbazepine, 600 mg b.i.d., levothyroxine, and trazodone. She had no hospitalizations and no temper outbursts or depressive episodes, was working full-time, and was not receiving Medicaid.
Mr. C was a 40-year-old married man who was referred to the clinic for treatment of agitation and conflict with his wife. He was taking buspirone, buproprion, and lithium. Oxcarbazepine, up to 1200 mg/day, was added to his dose of lithium, 900 mg/day. His irritability decreased, his depression lifted, his relationship with his wife improved, and he obtained full-time employment. In the past year, he has been well maintained with oxcarbazepine, 1200 mg b.i.d., and modafinil, 400 mg/day, before his shift work.
Mr. D was a 33-year-old man who was referred for treatment of domestic violence. He began oxcarbazepine monotherapy, up to 1200 mg/day. Since then, he has controlled his angry outbursts, felt happier, improved his home life, reduced his alcohol and cannabis consumption to occasional use, and given up his part-time job as a bar bouncer. His friends have also noted the improvement.
These patients were initially given 150 mg/day of oxcarbazepine; the dose was increased every 3–4 days by 150 mg until it reached 600 mg at bedtime. Morning dosing was then added, as needed, up to the maximum dose reported per patient. None of these patients had developed hyponatremia when tested within 1 month of initiation of treatment.
These patients showed improvement in mood stabilization. Oxcarbazepine was well tolerated and was the initiating factor in decreasing their symptoms of anger and irritability, as well as their depressive symptoms. We have also reported separately on the benefits of oxcarbazepine in a series of 87 patients with various subtypes of mood disorders (3). Prospective, double-blind, placebo-controlled trials of oxcarbazepine are indicated.

References

1.
Emrich HM, Altmann H, Dose M, von Zerssen D: Therapeutic effects of GABA-ergic drugs in affective disorders: a preliminary report. Pharmacol Biochem Behav 1983; 19:369-372
2.
Emrich HM, Dose M, von Zerssen D: The use of sodium valproate, carbamazepine and oxcarbazepine in patients with affective disorders. J Affect Disord 1985; 8:243-250
3.
Nasr SJ, Casper ML: Oxcarbazepine use in the treatment of mood disorders, in 2002 Annual Meeting New Research Program and Abstracts. Washington, DC, American Psychiatric Association, p 117

Information & Authors

Information

Published In

Go to American Journal of Psychiatry
Go to American Journal of Psychiatry
American Journal of Psychiatry
Pages: 1793
PubMed: 12359694

History

Published online: 1 October 2002
Published in print: October 2002

Authors

Affiliations

SUHAYL NASR, M.D.
Michigan City, Ind.

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

There are no citations for this item

View Options

View options

PDF/ePub

View PDF/ePub

Get Access

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Purchase Options

Purchase this article to access the full text.

PPV Articles - American Journal of Psychiatry

PPV Articles - American Journal of Psychiatry

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share